# Dysport in Post-Surgical Neuralgia

> **NCT03663101** · PHASE2 · COMPLETED · sponsor: **Ipsen** · enrollment: 16 (actual)

## Conditions studied

- Chronic Scar Pain

## Interventions

- **DRUG:** Lidocaine
- **BIOLOGICAL:** Botulinum toxin type A
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03663101
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-30
- **Primary completion:** 2019-11-08
- **Final completion:** 2019-11-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03663101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03663101, "Dysport in Post-Surgical Neuralgia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03663101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*